8 Analysts Assess Hims & Hers Health: What You Need To Know
Portfolio Pulse from Benzinga Insights
Eight analysts have recently evaluated Hims & Hers Health (NYSE:HIMS), with a mix of bullish and indifferent ratings. The average 12-month price target has increased to $19.5 from $16.75. Analysts have raised their price targets, reflecting positive sentiment and strong financial performance, including a 45.81% revenue growth rate and impressive profitability metrics.
June 13, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown a mix of bullish and indifferent ratings for Hims & Hers Health, with the average 12-month price target increasing to $19.5. The company's strong financial performance, including a 45.81% revenue growth rate and impressive profitability metrics, has contributed to this positive sentiment.
The increase in the average price target and the positive financial performance metrics such as revenue growth, net margin, ROE, and ROA indicate a likely positive short-term impact on HIMS stock price. Analysts' raised price targets and positive ratings reflect confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100